Biomerica, Inc.

NASDAQ (USD): Biomerica, Inc. (BMRA)

Last Price

0.83

Today's Change

+0.052 (6.68%)

Day's Change

0.771 - 0.896

Trading Volume

1,637,452

Overview

Market Cap

15 Million

Shares Outstanding

18 Million

Avg Volume

8,191,831

Avg Price (50 Days)

0.45

Avg Price (200 Days)

0.42

PE Ratio

-2.52

EPS

-0.33

Earnings Announcement

10-Apr-2025

Previous Close

0.78

Open

0.78

Day's Range

0.7707 - 0.8962

Year Range

0.24 - 1.35

Trading Volume

1,675,057

Price Change Highlight

1 Day Change

6.72%

5 Day Change

10.67%

1 Month Change

29.69%

3 Month Change

137.75%

6 Month Change

165.09%

Ytd Change

173.93%

1 Year Change

-18.63%

3 Year Change

-81.09%

5 Year Change

-70.46%

10 Year Change

-9.78%

Max Change

-84.19%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Medical Devices

Description:

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment